Lovisa Afzelius is an origination partner at Flagship Pioneering and co-founder, chief executive officer and director at Apriori Bio. A computational scientist by training, she brings to Flagship two decades of leadership experience and a passion for data-driven drug discovery. Lovisa has served as CEO, co-founder, president, board chairman, and executive director, in emerging biotechs and large pharma companies. She joined Flagship in early 2020, leading innovation as founding CEO of Alltrna as well as co-founder and CEO of Apriori Bio, FL72 and FL89.&nbsp; Before joining the Flagship ecosystem, Lovisa built and led Pfizer’s systems immunology function. In 2017, she co-founded Elsa.science, a digital health company for which she serves on the board. Lovisa began her career at AstraZeneca and has received numerous accolades for her work, including being named one of the 100 “most influential persons under 40 in Sweden” by the business magazine, Affärsvärlden. She holds a PhD in computational chemistry from Uppsala University, a Master of Science in integrative pharmacology from Gothenburg University as well as an MBA from MIT.

large_Lovisa Afzelius-New.jpg

Lovisa Afzelius, PhD, MBA

Co-founder and CEO, Apriori Bio

Origination Partner, Flagship Pioneering